Glanbia (GLAPY) Upgraded to Buy by Zacks Investment Research
Zacks Investment Research upgraded shares of Glanbia (OTCMKTS:GLAPY) from a hold rating to a buy rating in a research note issued to investors on Thursday. The brokerage currently has $97.00 price target on the stock.
According to Zacks, “Glanbia Plc engages in the manufacture and distribution of dairy and nutritional food products. Its operating segments include Glanbia Performance Nutrition, Global Ingredients, Dairy Ireland and Joint Ventures and Associates. Glanbia Performance Nutrition segment comprises of performance nutrition products under the Optimum Nutrition, BSN, Isopure, Nutramino and ABB brands. Global Ingredients segment includes American-style cheddar cheese, micro-nutrient premixes and dairy and non-dairy nutritional solutions. Dairy Ireland segment consists of consumer products and agribusiness. Joint Ventures and Associates segment covers Glanbia Ingredients Ireland, Glanbia Cheese and Southwest Cheese. Glanbia Plc is headquartered in Kilkenny, Ireland. “
Shares of GLAPY remained flat at $$86.37 during trading on Thursday. Glanbia has a 52 week low of $80.23 and a 52 week high of $98.16. The firm has a market cap of $5.11 billion, a price-to-earnings ratio of 17.14, a P/E/G ratio of 4.52 and a beta of -0.06. The company has a quick ratio of 1.20, a current ratio of 2.01 and a debt-to-equity ratio of 0.36.
Glanbia plc operates as a nutrition company worldwide. It operates through three segments: Glanbia Performance Nutrition, Glanbia Nutritionals, and Glanbia Ireland Joint Venture. The Glanbia Performance Nutrition segment offers powders, bars and snacking food, and ready-to-drink beverages through various channels, including specialty retail, the Internet, and gyms, as well as food, drug, mass, and club channels.
Further Reading: Trading Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glanbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glanbia and related companies with MarketBeat.com's FREE daily email newsletter.